Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Efzofitimod by ATyr Pharma for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval
Efzofitimod is under clinical development by ATyr Pharma and currently in Phase II for Interstitial Lung Diseases (Diffuse Parenchymal Lung...
Data Insights
Efzofitimod by ATyr Pharma for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Efzofitimod is under clinical development by ATyr Pharma and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData,...